+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia



Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia



Zhonghua Xue Ye Xue Za Zhi 40(1): 52-57



目的: 分析儿童核心结合因子相关性急性髓系白血病(CBF-AML)的疗效及预后因素。 方法: 对2005年8月至2017年9月收治住院的初诊CBF-AML患儿共121例进行回顾性研究。采用Kaplan-Meier曲线评估患儿的累积复发率(CIR)、无事件生存(EFS)率和总生存(OS)率,Cox回归模型评估预后因素。 结果: 121例患儿中,120例有化疗后骨髓缓解情况评估结果,1个疗程后完全缓解(CR)100例(83.3%),2个疗程后CR 119例(99.2%)。121例患儿中复发13例(10.7%),中位复发时间13.8(3.7~58.8)个月,死亡17例(14.0%)。全部患儿3年CIR、EFS、OS率分别为12.7%、77.5%、82.8%。对发病时年龄、性别、初诊时WBC、是否有髓外白血病、是否伴C-KIT突变、是否有附加染色体异常、第1个疗程是否达CR等进行Cox多因素回归分析,只有伴附加染色体异常是影响患儿OS的独立危险因素(HR=4.289,95%CI 1.070~17.183,P=0.040)。 结论: 儿童CBF-AML是一组独特的预后亚型,化疗疗效较好,伴附加染色体异常是影响患儿OS的独立危险因素。.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066446347

Download citation: RISBibTeXText

PMID: 30704229


Related references

Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. Pediatric Blood and Cancer 64(10), 2017

Study of clinical outcome and analysis of prognosis related factor in children with acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi 27(9): 621-625, 2007

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. Journal of Clinical Oncology 23(24): 5705-5717, 2005

Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. Haematologica 98(10): 1525-1531, 2014

Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leukemia and Lymphoma 50(9): 1448-1460, 2011

Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Review of Hematology 8(1): 43-56, 2015

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19(9): 1536-1542, 2005

Core binding factor acute myeloid leukemia Cancer and leukemia group B Study 8461. Annals of Hematology 83(Supplement 1): S84-S85, 2004

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 100(6): 780-785, 2016

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Annals of Hematology 83 Suppl 1: S84-S85, 2004

Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. Biology of Blood and Marrow Transplantation 14(11): 1262-1269, 2008

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. Journal of Clinical Oncology 22(18): 3741-3750, 2004

The clinical spectrum of adult acute myeloid leukemia (AML) associated with core binding factor (CBF) translocations. Journal of Clinical Oncology 23(16_suppl): 6513-6513, 2016

Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: Biology and clinical implications. Annals of Hematology 78(6): 251-264, 1999

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. Haematologica 99(10): E185-E187, 2015